A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Trial Profile

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs MEDI 8968 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Jul 2016 Status changed from completed to discontinued as no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.)
    • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top